Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 8/20 | 0.36 |
| ▸ | HTR2A | P28223 | 7/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.35 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.35 |
| ▸ | GRK2 | P25098 | 1/20 | 0.35 |
| ▸ | GRK5 | P34947 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22687941 | 0.91 | CDC7 (0.40) | CDC7KDRNPC1RAB9AHTR2C | |
| SCHEMBL21901897 | 0.88 | P2RX7 (0.35) | CDC7ROCK1GRK2SYK | |
| SCHEMBL21901171 | 0.79 | CDC7 (0.46) | CDC7KDRNPC1RAB9AHTR2C | |
| SCHEMBL29370016 | 0.79 | CDC7 (0.46) | CDC7KDRNPC1RAB9AHTR2C | |
| SCHEMBL21900969 | 0.79 | CDC7 (0.46) | CDC7KDRNPC1RAB9AHTR2C | |
| SCHEMBL21900948 | 0.78 | CDC7 (0.41) | CDC7KDRNPC1RAB9AHTR2C | |
| SCHEMBL29536029 | 0.78 | CDC7 (0.41) | CDC7KDRNPC1RAB9AHTR2C | |
| SCHEMBL21901264 | 0.76 | AXL (0.43) | MKNK1 | |
| SCHEMBL21901896 | 0.76 | NOS1 (0.35) | — | |
| SCHEMBL22655827 | 0.75 | CDC7 (0.39) | CDC7KDRNPC1RAB9AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331057-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240336614-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2024-10-10 | — | — | US | disclosed |
| CN-114096542-B | Condensed tricyclic pyrroles as alpha-1 antitrypsin modulators | 弗特克斯药品有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-11884672-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMA (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMA (US) | 2023-08-24 | — | — | US | disclosed |
| EP-3969440-A1 | CONDENSED TRICYCLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-114096542-A | Condensed tricyclic pyrroles as alpha-1 antitrypsin modulators | 弗特克斯药品有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2021-06-17 | — | — | US | disclosed |
| WO-2020247160-A1 | CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247160-A1 | CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
| WO-2020081257-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336614-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | CDC7 3618/4885KDR 4851/4885NPC1 675/4885 |
| US-11884672-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINC1, SERPINA3 | CDC7 3618/4885KDR 4851/4885NPC1 675/4885 |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | CDC7 3618/4885KDR 4851/4885NPC1 675/4885 |
| US-12331057-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINC1, SERPINA3 | CDC7 3618/4885KDR 4851/4885NPC1 675/4885 |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | CDC7 3537/4885KDR 4870/4885NPC1 509/4885 |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | CDC7 3537/4885KDR 4870/4885NPC1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.